Vanda Pharmaceuticals (VNDA) Interest Coverage Ratio Growth (3y) (2013 - 2026)
Vanda Pharmaceuticals (VNDA) Interest Coverage Ratio Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -42.41% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn | 28.11% |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn | -6.89% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 79.27% |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - | 29.47% |
| 10 | Vanda Pharmaceuticals | 313.51 Mn | 111.20 Mn | 48.56 Mn | -89.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -89.27% |
| Dec 31, 2025 | -162.56% |
| Sep 30, 2025 | -66.83% |
| Jun 30, 2025 | -83.62% |
| Mar 31, 2025 | -32.24% |
| Dec 31, 2024 | -43.27% |
| Sep 30, 2024 | -65.23% |
| Jun 30, 2024 | -78.21% |
| Mar 31, 2024 | -52.18% |
| Dec 31, 2023 | -36.80% |
| Sep 30, 2023 | -117.45% |
| Jun 30, 2023 | -46.07% |
| Mar 31, 2023 | 451.20% |
| Dec 31, 2022 | -46.49% |
| Sep 30, 2022 | 48.15% |
| Jun 30, 2022 | 41.44% |
| Mar 31, 2022 | -173.98% |
| Dec 31, 2021 | 146.84% |
| Sep 30, 2021 | 73.81% |
| Jun 30, 2021 | 52.91% |